HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmNEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Humacyte, Inc. (
NASDAQHUMA) on behalf of long-term stockholders following a class action complaint that was filed against Humacyte on November 18, 2024 with a Class Period from May 10, 2024 to October 17, 2024. Our investigation concerns whether the board of directors of Humacyte have breached their fiduciary duties to the company.
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. (“Humacyte” or “the Company”) (
NASDAQHUMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Humacyte, Inc. (
NASDAQHUMA) between May 10, 2024 and October 17, 2024. Humacyte describes itself as a company that “engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues.”
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMAFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Jan. 16, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. (“Humacyte” or “the Company”) (
NASDAQHUMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Deadline Soon: Humacyte, Inc. (HUMA) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz reminds investors of the upcoming January 17, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Humacyte, Inc. (“Humacyte” or the “Company”) (
NASDAQHUMA) securities between May 10, 2024 and October 17, 2024, inclusive (the “Class Period”).
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Wolfspeed, Xerox, Visa, and Humacyte and Encourages Investors to Contact the FirmNEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Wolfspeed, Inc. (
NYSEWOLF), Xerox Holdings Corporation
NASDAQ:XRXNASDAQXRX)
(NYSE: VNYSEV
, and Humacyte, Inc. (NASDAQ: HUMANASDAQ
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of HumacyteFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PACS Group, Chipotle, Hasbro, and Humacyte and Encourages Investors to Contact the FirmNEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of PACS Group, Inc. (
NYSEPACS), Chipotle Mexican Grill, Inc.
NYSE: CMGNYSECMG)
(NASDAQ: HASNASDAQHAS
, and Humacyte, Inc. (NASDAQ: HUMANASDAQ
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Kirby McInerney LLP Urges Investors in Humacyte, Inc. to Inquire About Their Rights in Class Action Lawsuit
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Middle District of North Carolina on behalf of those who acquired Humacyte, Inc. (“Humacyte” or the “Company”) (
NASDAQHUMA) securities between May 10, 2024, through October 17, 2024 (“the Class Period”). Investors have until January 17, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Humacyte to Contact Us to Have Their Losses Evaluated TodayFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the FirmNEW YORK, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or the “Company”) (
NASDAQHUMA) in the United States District Court for the Middle District of North Carolina on behalf of all persons and entities who purchased or otherwise acquired Humacyte securities between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”). Investors have until January 17, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the FirmNEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or the “Company”) (
NASDAQHUMA) in the United States District Court for the Middle District of North Carolina on behalf of all persons and entities who purchased or otherwise acquired Humacyte securities between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”). Investors have until January 17, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the FirmNEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or the “Company”) (
NASDAQHUMA) in the United States District Court for the Middle District of North Carolina on behalf of all persons and entities who purchased or otherwise acquired Humacyte securities between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”). Investors have until January 17, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of HumacyteFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the FirmNEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or the “Company”) (
NASDAQHUMA) in the United States District Court for the Middle District of North Carolina on behalf of all persons and entities who purchased or otherwise acquired Humacyte securities between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”). Investors have until January 17, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
